Immunology

Shaperon is developing a bispecific nanobody (Papiliximab®) targeting PD-L1 and CD47, a novel immunotherapy targeting both innate immunity (CD47/SIRP-a) and adaptive immunity (PD-1/PD-L1).

Designed to minimize hemagglutination with low binding affinity to CD47 on RBCs, Papiliximab® effectively blocks binding to PD-1/PD-L1 and activates CD4+ T lymphocytes. It can also effectively block the CD47/SIRP-a interaction and induce macrophages to phagocytize CD47-expressing tumor cells while minimizing hemagglutination.